Smoke Inhalation

ADULT PEDIATRIC

BLS Procedures

Remove individual from the environment

Consider gross decontamination

Assess ABCs

Assess for trauma and other acute medical conditions

Administer high flow oxygen as indicated, or with evidence of smoke inhalation and ALOC or significant headache

ALS Standing Orders

Airway support in accordance with Policy 710 – Airway Management

IV/IO access as indicated

If Wheezes present

- Albuterol
 - o Nebulizer 5 mg/6 mL
 - Repeat as needed

If smoke inhalation AND unconscious, ALOC, or cardiac arrest:

- Hydroxocobalamin If Available
 - o IV/IO 5 g in 200 mL NS over 15 minutes

Airway support in accordance with Policy 710 – Airway Management

IV/IO access as indicated

If Wheezes present

- Albuterol
 - o Patient ≤ 30 kg
 - Nebulizer 2.5 mg/3 mL
 - o Repeat as needed
 - Patient > 30 kg
 - Nebulizer 5 mg/6 mL
 - Repeat as needed

If smoke inhalation AND unconscious, ALOC, or cardiac arrest:

- Hydroxocobalamin If Available
 - IV/IO 70 mg/kg to a max of 5 g in 200 mL NS over 15 minutes

Base Hospital Orders Only

Continued unconscious/ALOC OR poor response to initial dose

- Hydroxocobalamin
 - IV/IO 5 g in 200 mL NS over 15 to 120 minutes, depending on clinical presentation.

Continued unconscious/ALOC OR poor response to initial dose

- Hydroxocobalamin
 - IV/IO 70 mg/kg to a max of 5 g in 200 mL NS over 15 to 120 minutes, depending on clinical presentation.

Consult with ED Physician for further treatment measures.

Additional Information:

- If monitoring equipment is available, the patient's carboxyhemoglobin levels should be checked if smoke inhalation is suspected.
- Evidence of smoke inhalation includes soot around mouth and/or nares, increased work of breathing, wheezing
- If additional IV/IO medications are indicated, establish a second IV or IO. DO NOT administer other medications with hydroxocobalamin through the same IV/IO line.
- DO NOT administer hydroxocobalamin if patient has a known allergy to hydroxocobalamin or cyanocobalamin

Effective Date: December 1, 2020 Next Review Date: October 31, 2022 Date Revised: October 8, 2020 Last Reviewed: October 8, 2020

VCEMS Medical Director